Prelude Therapeutics narrows Q1 2026 net loss to $10.4 million from $32.1 million
Prelude Therapeutics reported first quarter 2026 results, with a net loss of $10.4 million, or $0.13 per share, compared with $32.1 million, or $0.42 per share, a year earlier. The company recorded $4.6 million of revenue, versus none in the prior-year period, and lower research and development and general and administrative expenses. It said its cash runway now extends into the second quarter of 2028, based on preliminary estimates that reflect an underwritten offering with about $90 million in gross proceeds completed after March 31.
Key points
- Net loss was $10.4 million, or $0.13 per share, for the three months ended March 31, 2026, versus $32.1 million, or $0.42 per share, a year earlier.
- Revenue was $4.6 million in the quarter, compared with no revenue in the prior-year period.
- Research and development expense fell to $13.6 million from $28.8 million, mainly due to lower spending on SMARCA2 trials paused in 2025.
- Cash, cash equivalents, restricted cash and marketable securities were $84.8 million on March 31, 2026, before the offering of about $90 million in gross proceeds.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 12, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.